Journal Article Summary
The article focuses on the growing interest in glucagon-like peptide-1 (GLP-1) agonists and their potential cardiovascular benefits, particularly for patients with diabetes. As cardiovascular diseases (CVDs) are a leading cause of death globally, understanding how GLP-1 agonists can help manage these conditions is crucial. The authors conducted a bibliometric analysis to evaluate the research trends and scholarly output related to GLP-1 agonists in the context of cardiovascular health, aiming to inform clinical practices and future research directions.
To carry out this analysis, the authors collected data from the Web of Science Core Collection, identifying 1,686 relevant articles published on GLP-1 agonists and cardiovascular diseases. They utilized various software tools to visualize publication trends, key contributors, and emerging research themes. The findings revealed a significant increase in publications since 2016, with the United States and China being the leading contributors. Notable research topics included newer GLP-1 agonists like tirzepatide and semaglutide, as well as areas such as "healthy obesity" and chronic kidney disease, indicating a shift towards exploring the broader therapeutic applications of these medications.
Despite the comprehensive nature of this bibliometric analysis, there are limitations to consider. The reliance on a single database may have excluded relevant studies indexed elsewhere, and the search strategy might not have captured all pertinent articles. Patients and caregivers should discuss the findings and implications of GLP-1 agonists with healthcare professionals, especially regarding their potential cardiovascular benefits and the management of diabetes and related conditions. Understanding these aspects can help in making informed decisions about treatment options.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Mahapatro Abinash, Bozorgi Ali, Obulareddy Sri U.J., Jain Shika M., Reddy Korsapati Rohan, Kumar Aroon, Patel Kristina, Soltani Moghadam Saman, et al.. Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023. Annals of Medicine and Surgery 2024. DOI: 10.1097/MS9.0000000000002592. PMID: 39525800. PMCID: PMC11543192.
Featured Pill Pals Product
Tirzepatide --- 72 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Tirzepatide — 72 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
